Hans-Joachim Lueck

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Martine Piccart, Marion Procter, Debora Fumagalli et al. · Journal of Clinical Oncology · 2021 · 359 citations · Full text

Medicine, Oncology, Pharmacology +17

Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases

Florian Heitz, Philipp Harter, Hans-Joachim Lueck et al. · European Journal of Cancer · 2009 · 224 citations

Medicine, Oncology, Breast Oncology +15

Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens

Andreas du Bois, B. Weber, Justine Rochon et al. · Journal of Clinical Oncology · 2006 · 196 citations · Full text

Medicine, Oncology, Pharmacology +17

Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study

Volker Moebus, Christian Jackisch, Hans-Joachim Lueck et al. · Journal of Clinical Oncology · 2010 · 192 citations · Full text

Medicine, Oncology, Pharmacotherapy +15